---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-012417"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:34:51.292079+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted

## Summary
- Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
- Common stock (IMNN) to continue trading on Nasdaq Capital Market without interruption.
- CEO notes recent 15% stock dividend and momentum from Phase 2 OVATION 2 trial for IMNN-001 in ovarian cancer.
- Phase 3 OVATION 3 trial for IMNN-001 successfully initiated in North America.

## SEC filing metadata
- accession: 0001493152-25-012417
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/0001493152-25-012417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-012417
- JSON: https://secwatch.observer/filing/0001493152-25-012417.json
- Plain text: https://secwatch.observer/filing/0001493152-25-012417.txt

## Key facts
- Listing & Compliance Notices
  Imunon, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315225012417/0001493152-25-012417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.